Posted by Michael Wonder on 01 Dec 2022
Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it often leads to side effects, some of which are serious.
Olaparib has recently been approved for the adjuvant, i.e. supportive, treatment of early stage breast cancer. It is an option for people with BRCA1/2 mutations who have HER2 negative breast cancer with a high risk of recurrence who have already been treated with chemotherapy in addition to surgery.
